keyword
MENU ▼
Read by QxMD icon Read
search

interferon beta-1a

keyword
https://www.readbyqxmd.com/read/28080250/no-evidence-of-disease-activity-in-patients-receiving-daclizumab-versus-intramuscular-interferon-beta-1a-for-relapsing-remitting-multiple-sclerosis-in-the-decide-study
#1
Ludwig Kappos, Eva Havrdova, Gavin Giovannoni, Bhupendra O Khatri, Susan A Gauthier, Steven J Greenberg, Xiaojun You, Ping Wang, Giorgio Giannattasio
BACKGROUND: No evidence of disease activity (NEDA) is a composite endpoint being increasingly applied as an outcome measure in clinical trials as well as proposed for individual therapeutic decisions in multiple sclerosis (MS). OBJECTIVE: Assess the proportion of patients with relapsing-remitting MS achieving NEDA in the DECIDE study of daclizumab 150 mg subcutaneous versus intramuscular interferon beta-1a 30 µg for 96-144 weeks. METHODS: NEDA was defined as no relapses, no onset of 12-week confirmed disability progression (CDP), no new/newly enlarging T2 hyperintense lesions (NET2), and no gadolinium-enhancing (Gd(+)) lesions...
December 1, 2016: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28027680/comparative-effectiveness-of-interferons-in-relapsing-remitting-multiple-sclerosis-a-meta-analysis-of-real-world-studies
#2
Thomas R Einarson, Basil G Bereza, Márcio Machado
BACKGROUND: Differences between interferons have been evaluated for over 20 years. While RCT data are mainly used for assessments and strong data for causal inferences, they do not necessarily reflect everyday practice. Real-world data may provide additional information. PURPOSE: To assess the results, quality, and representativeness of observational studies directly comparing IFNs in RRMS. METHODS: Medline and Embase were searched for observational studies comparing IFN-beta-1a 30 mcg IM (Avonex), IFN-beta-1a 44 mcg SC (Rebif) and/or IFN-beta-1b 250 mcg SC (Betaseron)...
December 27, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28002679/ocrelizumab-versus-interferon-beta-1a-in-relapsing-multiple-sclerosis
#3
Stephen L Hauser, Amit Bar-Or, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Xavier Montalban, Kottil W Rammohan, Krzysztof Selmaj, Anthony Traboulsee, Jerry S Wolinsky, Douglas L Arnold, Gaelle Klingelschmitt, Donna Masterman, Paulo Fontoura, Shibeshih Belachew, Peter Chin, Nicole Mairon, Hideki Garren, Ludwig Kappos
Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 μg three times weekly for 96 weeks. The primary end point was the annualized relapse rate. Results The annualized relapse rate was lower with ocrelizumab than with interferon beta-1a in trial 1 (0...
19, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/27999525/antidepressant-drug-treatment-in-association-with-multiple-sclerosis-disease-modifying-therapy-using-explorys-in-the-ms-population
#4
Matthew M Mirsky, Ruth Ann Marrie, Alexander Rae-Grant
Background: The Explorys Enterprise Performance Management (EPM) database contains de-identified clinical data for 50 million patients. Multiple sclerosis (MS) disease-modifying therapies (DMTs), specifically interferon beta (IFNβ) treatments, may potentiate depression. Conflicting data have emerged, and a large-scale claims-based study by Patten et al. did not support such an association. This study compares the results of Patten et al. with those using the EPM database. Methods: "Power searches" were built to test the relationship between antidepressant drug use and DMT in the MS population...
November 2016: International Journal of MS Care
https://www.readbyqxmd.com/read/27995531/effect-on-cognition-of-estroprogestins-combined-with-interferon-beta-in-multiple-sclerosis-analysis-of-secondary-outcomes-from-a-randomised-controlled-trial
#5
Laura De Giglio, Fabiana Marinelli, Valeria T Barletta, Veronica A Pagano, Floriana De Angelis, Fulvia Fanelli, Nikolaos Petsas, Patrizia Pantano, Valentina Tomassini, Carlo Pozzilli
INTRODUCTION: Cognitive impairment is a disabling symptom in multiple sclerosis (MS). While its management remains challenging, beneficial effects on cognition of interferon beta (IFN-β) have been reported and a positive effect from estroprogestins has been hypothesised, suggesting that the combination of the two medications in women with MS could offer a promising treatment strategy. OBJECTIVES: We investigated whether a combination of estroprogestins and IFN-β can improve cognition in women with MS...
December 19, 2016: CNS Drugs
https://www.readbyqxmd.com/read/27970906/quality-of-life-in-relapsing-remmiting-multiple-sclerosis-influence-of-interferon-beta-1a-avonex-and-cinnovex-treatment
#6
rS Shahtaheri, N Hatam
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970905/impact-of-adherence-on-subcutaneous-interferon-beta-1a-effectiveness-administered-by-rebismart%C3%A2-in-patients-with-multiple-sclerosis
#7
M Edo-Solsona, E Monte-Boquet, B Casanova-Estruch, J Poveda-Andrés
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27942880/erratum-to-spontaneous-regression-of-a-parafalcine-meningioma-in-a-multiple-sclerosis-patient-being-treated-with-interferon-beta-1a
#8
Luke Galloway, Niki Vakili, Julian Spears
No abstract text is available yet for this article.
December 10, 2016: Acta Neurochirurgica
https://www.readbyqxmd.com/read/27919500/favorable-outcome-of-interferon-beta-associated-thrombotic-microangiopathy-following-treatment-with-corticosteroids-plasma-exchange-and-rituximab-a-case-report
#9
Lea M Gerischer, Eberhard Siebert, Oliver Janke, Gerhard Jan Jungehuelsing, Klemens Ruprecht
Thrombotic microangiopathy (TMA) is a rare but increasingly recognized complication of interferon-beta therapy, which can be associated with serious sequelae. We report on a 53-year-old woman with a longstanding history of relapsing-remitting multiple sclerosis, who developed TMA after 15 years of high-dose treatment with subcutaneous interferon-beta-1a. The patient presented with headaches, an epileptic seizure, confusion, and arterial hypertension. Laboratory findings included thrombocytopenia and hemolytic anemia...
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27885061/alemtuzumab-improves-quality-of-life-outcomes-compared-with-subcutaneous-interferon-beta-1a-in-patients-with-active-relapsing-remitting-multiple-sclerosis
#10
Rafael Arroyo González, Mariko Kita, Heidi Crayton, Eva Havrdova, David H Margolin, Stephen L Lake, Gavin Giovannoni
BACKGROUND: Alemtuzumab was superior on clinical and magnetic resonance imaging (MRI) outcomes versus subcutaneous interferon beta-1a in phase 3 trials in patients with relapsing-remitting multiple sclerosis. OBJECTIVE: To examine quality-of-life (QoL) outcomes in the alemtuzumab phase 3 trials. METHODS: Patients who were treatment naive (Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis I [CARE-MS I]) or had an inadequate response to prior therapy (CARE-MS II) received annual courses of alemtuzumab 12 mg/day at baseline (5 days) and Month 12 (3 days) or subcutaneous interferon beta-1a 44 µg three times/week...
November 1, 2016: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/27880972/interferons-beta-versus-glatiramer-acetate-for-relapsing-remitting-multiple-sclerosis
#11
REVIEW
Loredana La Mantia, Carlo Di Pietrantonj, Marco Rovaris, Giulio Rigon, Serena Frau, Francesco Berardo, Anna Gandini, Anna Longobardi, Bianca Weinstock-Guttman, Alberto Vaona
BACKGROUND: Interferons-beta (IFNs-beta) and glatiramer acetate (GA) were the first two disease-modifying therapies (DMTs) approved 20 years ago for the treatment of multiple sclerosis (MS). DMTs' prescription rates as first or switching therapies and their costs have both increased substantially over the past decade. As more DMTs become available, the choice of a specific DMT should reflect the risk/benefit profile, as well as the impact on quality of life. As MS cohorts enrolled in different studies can vary significantly, head-to-head trials are considered the best approach for gaining objective reliable data when two different drugs are compared...
24, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27873050/spontaneous-regression-of-a-parafalcine-meningioma-in-a-multiple-sclerosis-patient-being-treated-with-interferon-beta-1a
#12
Luke Galloway, Niki Vakili, Julian Spears
Regression of meningioma after haemorrhage and the cessation of hormone treatment is well reported. However, spontaneous regression is very rarely observed. Here, we report the spontaneous regression of a parafalcine meningioma in a 56-year-old woman with multiple sclerosis, who was referred to our department after an incidental finding on magnetic resonance imaging. She was being treated with interferon beta-1a to manage the symptoms. To our knowledge, this is the first report of spontaneous regression of meningioma in a patient receiving interferon beta-1a therapy and just the second report of spontaneous regression in general...
November 21, 2016: Acta Neurochirurgica
https://www.readbyqxmd.com/read/27846348/pharmacological-treatment-other-than-corticosteroids-intravenous-immunoglobulin-and-plasma-exchange-for-guillain-barr%C3%A3-syndrome
#13
REVIEW
Jane Pritchard, Richard Ac Hughes, Robert Dm Hadden, Ruth Brassington
BACKGROUND: Plasma exchange and intravenous immunoglobulin, but not corticosteroids, are beneficial in Guillain-Barré syndrome (GBS). The efficacy of other pharmacological agents is unknown. This review was first published in 2011 and updated in 2013 and 2016. OBJECTIVES: To assess the effects of pharmacological agents other than plasma exchange, intravenous immunoglobulin and corticosteroids for GBS. SEARCH METHODS: On 18 January 2016, we searched the Cochrane Neuromuscular Specialised Register, Cochrane Central Register of Controlled Trials, MEDLINE, and Embase for treatments for GBS...
15, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27835061/peginterferon-beta-1a-shows-antitumor-activity-as-a-single-agent-and-enhances-efficacy-of-standard-of-care-cancer-therapeutics-in-human-melanoma-breast-renal-and-colon-xenograft-models
#14
Antonio Boccia, Cyrus Virata, Daniel Lindner, Nicki English, Nuzhat Pathan, Margot Brickelmaier, Xiao Hu, Jennifer L Gardner, Liaomin Peng, Xinzhong Wang, Xiamei Zhang, Lu Yang, Keli Perron, Grace Yco, Rebecca Kelly, James Gamez, Thomas Scripps, Donald Bennett, Ingrid B Joseph, Darren P Baker
Because of its tumor-suppressive effect, interferon-based therapy has been used for the treatment of melanoma. However, limited data are available regarding the antitumor effects of pegylated interferons, either alone or in combination with approved anticancer drugs. We report that treatment of human WM-266-4 melanoma cells with peginterferon beta-1a induced apoptotic markers. Additionally, peginterferon beta-1a significantly inhibited the growth of human SK-MEL-1, A-375, and WM-266-4 melanoma xenografts established in immunocompromised mice...
November 11, 2016: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/27828855/the-cross-reactivity-of-binding-antibodies-with-different-interferon-beta-formulations-used-as-disease-modifying-drugs-in-multiple-sclerosis-patients
#15
Agnieszka Wencel-Warot, Slawomir Michalak, Marcin Warot, Alicja Kalinowska-Lyszczarz, Radoslaw Kazmierski
Interferon beta (IFNb) preparations are commonly used as first-line therapy in relapsing-remitting multiple sclerosis (RRMS). They are, however, characterized by limited efficacy, partly due to the formation of anti-IFNb antibodies in patients.In this pilot study, we assessed with the ELISA method the presence of the binding antibodies (BAbs) against interferon beta after 2 years of therapy with subcutaneous interferon beta 1a (Rebif) in 49 RRMS patients. Antibody levels were established again within 1 year after treatment withdrawal...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27822961/the-cost-effectiveness-of-disease-modifying-therapies-for-the-treatment-of-relapsing-remitting-multiple-sclerosis
#16
Duygu Bozkaya, Terrie Livingston, Kristen Migliaccio-Walle, Tanner Odom
BACKGROUND: The safety and efficacy of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) has been established; however, it is not clear which provides optimal value, given benefit-risk profiles and costs. AIMS: To compare the cost-effectiveness of current DMTs for patients with RRMS in the US. MATERIALS AND METHODS: A Markov model predicting RRMS course following initiation of a DMT was created comparing outcomes (e...
November 21, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27806057/occurrence-of-anti-drug-antibodies-against-interferon-beta-and-natalizumab-in-multiple-sclerosis-a-collaborative-cohort-analysis
#17
Delphine Bachelet, Signe Hässler, Cyprien Mbogning, Jenny Link, Malin Ryner, Ryan Ramanujam, Michael Auer, Poul Erik Hyldgaard Jensen, Nils Koch-Henriksen, Clemens Warnke, Kathleen Ingenhoven, Dorothea Buck, Verena Grummel, Andy Lawton, Naoimh Donnellan, Agnès Hincelin-Mery, Dan Sikkema, Marc Pallardy, Bernd Kieseier, Bernard Hemmer, Hans Peter Hartung, Per Soelberg Sorensen, Florian Deisenhammer, Pierre Dönnes, Julie Davidson, Anna Fogdell-Hahn, Philippe Broët
Immunogenicity of biopharmaceutical products in multiple sclerosis is a frequent side effect which has a multifactorial etiology. Here we study associations between anti-drug antibody (ADA) occurrence and demographic and clinical factors. Retrospective data from routine ADA test laboratories in Sweden, Denmark, Austria and Germany (Dusseldorf group) and from one research study in Germany (Munich group) were gathered to build a collaborative multi-cohort dataset within the framework of the ABIRISK project. A subset of 5638 interferon-beta (IFNβ)-treated and 3440 natalizumab-treated patients having data on at least the first two years of treatment were eligible for interval-censored time-to-event analysis...
2016: PloS One
https://www.readbyqxmd.com/read/27800257/peripheral-vasculitis-intermediate-uveitis-and-interferon-use-in-multiple-sclerosis
#18
Şeref Kinyas, Haluk Esgin
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. A 40-year-old female patient with a 12-year history of MS was admitted to our clinic with blurred vision and floaters in her right eye for about 1 month. Here, we share the findings and the management of intermediate uveitis and retinal periphlebitis in an MS case being treated with interferon beta-1a for 7 years.
January 2016: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/27730845/peginterferon-beta-1a-versus-other-self-injectable-disease-modifying-therapies-in-the-treatment-of-relapsing-remitting-multiple-sclerosis-in-scotland-a-cost-effectiveness-analysis
#19
Luis Hernandez, Shien Guo, Hector Toro-Diaz, Stuart Carroll, Syed Feisal Syed Farooq
AIMS: Peginterferon beta-1a 125 mcg administered subcutaneously every two weeks, a new disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS), was approved in January 2015 by the Scottish Medicines Consortium. This study assesses long-term clinical and economic outcomes of peginterferon beta-1a compared with other self-injectable DMTs (interferon beta-1a [22 mcg, 30 mcg, and 44 mcg], interferon beta-1b, and glatiramer acetate 20 mg) in the treatment of RRMS, from the National Health Service and personal social services perspective in Scotland...
October 12, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27716096/the-effect-of-intramuscular-interferon-beta-1a-on-spinal-cord-volume-in-relapsing-remitting-multiple-sclerosis
#20
Sheena L Dupuy, Fariha Khalid, Brian C Healy, Sonya Bakshi, Mohit Neema, Shahamat Tauhid, Rohit Bakshi
BACKGROUND: Spinal cord atrophy occurs early in multiple sclerosis (MS) and impacts disability. The therapeutic effect of interferon beta-1a (IFNβ-1a) on spinal cord atrophy in patients with relapsing-remitting (RR) MS has not been explored. METHODS: We retrospectively identified 16 consecutive patients receiving weekly intramuscular IFNβ-1a for 2 years [baseline age (mean ± SD) 47.7 ± 7.5 years, Expanded Disability Status Scale score median (range) 1...
October 5, 2016: BMC Medical Imaging
keyword
keyword
80155
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"